Sirtuins as Therapeutic Targets for Treating Cancer, Metabolic Diseases, and Neurodegenerative Diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing molecular mechanisms and disease pathways without systematic search methodology.
PubMed 41304967 · doi:10.3390/ph18111723
What was done
This narrative review summarizes the biological roles, post-translational modifications, and mechanisms of action of the seven human NAD+-dependent sirtuin isoforms (SIRT1 to 7). It evaluates published literature on the roles of sirtuins in the pathogenesis and progression of cancer, metabolic disorders, and neurodegenerative diseases (specifically Alzheimer's disease, Parkinson's disease, and Huntington's disease), as well as the therapeutic potential of sirtuin inhibitors and activators.
What was found
The abstract reports no quantitative results, sample sizes, or numerical effect sizes. It notes that all seven isoforms (SIRT1–7) have been implicated in cancer development, whereas SIRT1–3 and SIRT6 are specifically associated with metabolic and neurodegenerative disease processes.
Why it matters
It outlines how targeting NAD+-dependent deacetylation mechanisms could yield therapeutic modulators across multiple major disease classes sharing underlying metabolic and stress-response dysregulation.
Limits
As a narrative review, it lacks a systematic search strategy, explicit study selection criteria, and formal risk-of-bias assessment. The abstract does not distinguish between bench or animal model findings and human clinical data, nor does it provide evidence on the pharmacokinetic viability, efficacy, or safety of specific sirtuin modulators in clinical settings.
Cited by
- supports Sirtuins require NAD as a cofactor/fuel to regulate gene expression and repair broken DNA.